A new FDA advisory panel meeting, influenced by RFK Jr.'s push for broader access, will weigh the potential benefits and risks of widely promoted peptides. Click the link in bio to read BPC 157 and the Difference Between an Evidence Gap and a Cover Up: What the entire human evidence base actually looks like, and the questions to ask next. WellFounded Founders Health & Full article: Compounded glucagon like peptide 1 receptor agonists for weight loss: the direct to consumer market in Colorado FDA Compliance for Peptide Therapy and BPC 157 Holt Law When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions Frontiers Syzygium aromaticum (clove buds) as a natural antibacterial agent: a promising alternative to combat multidrug resistant bacteria